Baloxavir manufacturers
- Baloxavir
-
- $71.00 / 1mg
-
2025-12-29
- CAS:1985605-59-1
- Min. Order:
- Purity: 99.46%
- Supply Ability: 10g
- Baloxavir
-
- $71.00 / 1mg
-
2025-12-29
- CAS:1985605-59-1
- Min. Order:
- Purity: 99.46%
- Supply Ability: 10g
- Baloxavir
-
- $0.00 / 100g
-
2025-12-25
- CAS:1985605-59-1
- Min. Order: 10g
- Purity: 0.99
- Supply Ability: 5000g
|
| | Baloxavir Basic information | | Uses |
| Product Name: | Baloxavir | | Synonyms: | Baloxavir;CPD2051;Baloxavir Impurity 10;S-033447;New Baloxavir;1H-[1,4]Oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, 12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,12,12a-tetrahydro-7-hydroxy-, (12aR)-;Baloxavir USP/EP/BP;(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2’4]triazine-6,8- dione | | CAS: | 1985605-59-1 | | MF: | C24H19F2N3O4S | | MW: | 483.49 | | EINECS: | 200-001-8 | | Product Categories: | API;1985605-59-1 | | Mol File: | 1985605-59-1.mol |  |
| | Baloxavir Chemical Properties |
| Boiling point | 644.7±65.0 °C(Predicted) | | density | 1.63±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:41.67(Max Conc. mg/mL);86.19(Max Conc. mM) | | form | A solid | | pka | 4.50±1.00(Predicted) | | color | White to yellow | | InChIKey | FIDLLEYNNRGVFR-CTNGQTDRSA-N | | SMILES | N12C=CC(=O)C(O)=C1C(=O)N1CCOC[C@@]1([H])N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C21 | | CAS DataBase Reference | 1985605-59-1 |
| | Baloxavir Usage And Synthesis |
| Uses | Baloxavir is a drug employed in the treatment of influenza virus infection.
Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. | | Uses | Baloxavir is a drug employed in the treatment of influenza virus infection. | | Mechanism of action | Baloxavir marboxil is an influenza therapeutic agent, specifically, an enzyme inhibitor targeting the influenza virus' cap-dependent endonuclease activity, one of the activities of the virus polymerase complex. In particular, it inhibits a process known as cap snatching, by which the virus derives short, capped primers from host cell RNA transcripts, which it then uses for polymerase-catalyzed synthesis of its needed viral mRNAs. A polymerase subunit binds to the host pre-mRNAs at their 5' caps, then the polymerase's endonuclease activity catalyzes its cleavage "after 10–13 nucleotides". As such, its mechanism is distinct from neuraminidase inhibitors such as oseltamivir and zanamivir. | | Side effects | Common side effects following the single dose administration of baloxavir marboxil include diarrhea, bronchitis, common cold, headache, and nausea. Adverse events were reported in 21% of people who received baloxavir, 25% of those receiving placebo, and 25% of oseltamivir. |
| | Baloxavir Preparation Products And Raw materials |
|